Since Alvotech was founded eight years ago, the Alvogen sister company has put in place development programs and manufacturing capabilities that have allowed it to build up a significant portfolio of biosimilars that are now progressing towards launch. And in recent years, Alvotech founder and chairman Robert Wessman explains to Generics Bulletin in the first part of an exclusive interview, a series of deals with some of the off-patent industry’s biggest players around the globe has provided the firm with a marketing network through which its products can reach payers and patients worldwide.
“When we started our journey in 2012, we basically said we want to build a company which would be fully...
